Global market

  • Inflammatory Bowel Disease (IBD) is a set of diseases that affect the digestive tract causing inflammatory processes. Its incidence has increased over the past few decades in industrialized countries, where it is estimated to affect more than 2.5 million people in Europe and 1 million people in the United States.
  • Crohn's disease and ulcerative colitis are the two main forms of IBD. Both conditions share the chronic nature alternating periods of active inflammation with periods of remission, so it requires a continuous evaluation of the activity that allows to adapt the therapeutic strategy and limit the progression of the disease and its complications.

Our proposal

  • The microbiological signature has been defined in 111 intestinal biopsies of patients with Crohn's disease and ulcerative colitis where its endoscopic activity has been evaluated. The identification of these bacteria in the adherent intestinal mucosa avoids variations in the determination due to dietary and population changes. This clinical study took place at the University Hospital Dr. Josep Trueta.
  • The optimization of the microbiological signature in stool samples was carried out through a multicenter study with 133 patients of Crohn’s disease and ulcerative colitis. The participating hospitals were Josep Trueta University Hospital, Bellvitge University Hospital and Germans Trias i Pujol Hospital.
  • The clinical validation was performed with a multicenter study with 100 patients of Cohn’s disease and Ulcerative Colitis in Josep Trueta University Hospital, Bellvitge University Hospital and Germans Trias i Pujol Hospital.
  • In addition, the capacity of the RAID-Monitor has been contrasted with a cohort of patients with Crohn’s disease and ulcerative colitis from Deaconess Beth Israel in Boston, USA.

RAID-Monitor is on the market for patients who have been diagnosed with Crohn’s disease or ulcerative colitis.

2019 InSiGHT Meeting

2019 InSiGHT Meeting

By goodgut.eu, On 20 de March de 2019

The International Society for Gastrointestinal Hereditary Tumours (InSiGHT) and the New Zealand Society ...